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Helicobacter Pylori colonizes the human gastric epithelium and causes diseases such as gastritis, peptic ulcers, and stomach cancer.
Undecaprenyl pyrophosphate synthase (UPPS), which catalyzes consecutive condensation reactions of farnesyl pyrophosphate
with eight isopentenyl pyrophosphate to form lipid carrier for bacterial peptidoglycan biosynthesis, represents a potential target
for developing new antibiotics. In this study, we solved the crystal structure of H. pylori UPPS and performed virtual screening
of inhibitors from a library of 58,635 compounds. Two hits were found to exhibit diﬀerential activities against Helicobacter Pylori
and Escherichia coli UPPS, giving the possibility of developing antibiotics specially targeting pathogenic H. pylori without killing
the intestinal E. coli.
Copyright © 2008 Chih-Jung Kuo et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Undecaprenyl pyrophosphate synthase (UPPS) catalyzes
consecutive condensation reactions of farnesyl pyrophos-
phate (FPP) with eight molecules of isopentenyl pyrophos-
phate(IPP)toformC55 undecaprenylpyrophosphate(UPP),
which acts as a lipid carrier to mediate bacterial peptido-
glycan biosynthesis [1, 2]. This enzyme belongs to a group
of cis-prenyltransferases which catalyze cis-double bonds
during IPP condensation reactions [3, 4]. UPPS was ﬁrst
cloned fromMicrococcusluteus and Escherichiacoli, and their
amino acid sequences were found conserved among the cis-
prenyltransferases, but totally diﬀerent from those of the
trans-prenyltransferases [5–7], implying diﬀerent catalytic
mechanism [8, 9].
HelicobacterPyloriisapathogenwhichcauseschronicin-
ﬂammation in the stomach [10]. The infection may evolve
to peptic ulcerations and gastric neoplasias. Due to its un-
usual ability to survive in stomach under the low pH con-
dition via proton pumps, H. Pylori infection becomes wide
spreading and accounts for the increased cases of stomach
carcinogenesis [11]. Antibiotics, such as proton pump in-
hibitors (PPI), amoxicillin, and clarithromycin, are used to
treat the infected patients. When failed, empirical quadru-
pletherapy(PPI-bismuch-tetracyclin-metronidazole)isthen
used as the second-line therapy [12]. Since UPPS is essential
for bacterial survival, it could possibly serve as a target for
new antibiotics. Even though the complex structures of E.
coli UPPS with the FPP substrate or with its analogue (far-
nesyl thiopyrophosphate, FsPP) and IPP have been obtained
[9, 13], no UPPS structure-derived inhibitors have been re-
ported so far. As shown in this study, we solved the crystal
structures of H. pylori UPPS and performed structure-based
inhibitor discovery. Two hits were discovered through com-
puter virtual screening from 58,635 compounds, which ex-
hibited diﬀerent level of inhibition against E. coli and H. py-
lori UPPS.
2. MATERIALS AND METHODS
2.1. OverexpressionofH.pyloriUPPS
The gene encoding UPPS from the H. pylori (ATCC43504)
genomic DNA was ampliﬁed by using polymerase chain2 Journal of Biomedicine and Biotechnology
reaction (PCR). The forward primer 5 -GGTATTGA-
GGGTCGCTTGGATAGCACTCTCAAA-3  and reverse
primer 5 -AGAGGAGAGTTAGAGCCCTAGCATTTTAA-
TTCCCC-3  were utilized in the PCR. The PCR product was
puriﬁed from 0.8% agarose gel electrophoresis. The DNA
product was ligated with pET-32Xa/LIC vector and trans-
formed into E. coli BL21 (DE3) for protein expression as pre-
viously described for expressing E. coli UPPS [14].
The C234A mutant was prepared by using QuikChange
Site-Directed Mutagenesis Kit in conjunction with the wild-
type gene template in the pET32Xa/Lic vector. The muta-
genic forward primer was 5 -CGCAAATTCGGGGAATTA-
AAA GCC TAGTGAGGCTCTAACTCT-3 . The procedure
of mutagenesis utilized a supercoiled double-stranded DNA
(dsDNA) vector with an insert of interest and two synthetic
forward and backward primers containing the desired muta-
tion. The mutation was conﬁrmed by sequencing the entire
UPPS mutant gene of the plasmid obtained from overnight
culture. The correct construct was subsequently transformed
to E. coli BL21(DE3) for protein expression. The procedure
for protein puriﬁcation followed our reported protocol [15].
Each puriﬁed mutant UPPS was veriﬁed by mass spectro-
scopic analysis and its purity (>9 5 % )w a sc h e c k e db yS D S -
PAGE.
2.2. Crystallizationanddatacollection
H. pylori C234A UPPS mutant was crystallized using the
hanging drop method from Hampton Research (Laguna
Niguel, Calif, USA) by mixing 2μL of the UPPS solution
(10mg/mL in 25mM Tris, 150mM NaCl, pH 8.0) with 2μL
of the mother liquor (0.15M KSCN, 15% PEG600, and 2%
PEG5KMME), and equilibrating with 500μL of the mother
liquor. Within 4 days, crystals grew to dimensions of about
0.5×0.5×0.2mm, and then the crystals were soaked with a
cryoprotectant solution of 0.2M KSCN, 30% PEG600, and
5% PEG5KMME for 1day. The structure of the C234A H.
pylori UPPS in complex with FsPP was obtained by soaking
the crystals with cryoprotectant solution of 2.5mM MgCl2,
2.5mM IPP, 2.5mM FsPP, 0.15M KSCN, 15% PEG600, and
2% PEG5KMME. However, only the pyrophosphate of FsPP
was found in the complex structure. The X-ray diﬀraction
datasets for the structures of the C234A UPPS mutant and
the complex with FsPP were collected to 1.88 ˚ Aa n d2 . 5˚ A
resolution, respectively. Data for the C234A UPPS crystals
were collected at beam line BL17B2 of the National Syn-
chrotron Radiation Research Center (NSRRC, Hsinchu, Tai-
wan). Data for the C234A UPPS complexed with FsPP were
collected in house using a Rigaku MicroMax002 X-ray gen-
erator equipped with an R- A x i sI V + +i m a g ep l a t ed e t e c t o r .
The diﬀraction data were processed using the programs of
HKL and HKL2000 [16]. Statistics for the dataset are listed
in Table 1. Prior to use in structural reﬁnements, 5% ran-
domly selected reﬂections were set aside for calculating Rfree
as a monitor [17].
2.3. Structuredeterminationandreﬁnement
The crystal structure of C234A UPPS was determined by
molecular replacement method using the Crystallography &
Table 1: Data collection and reﬁnement statistics for the or-
thorhombicH.pyloriUPPScrystalsoftheapoenyzme andthecom-
plexwiththiopyrophosphate.C234Amutationwasincludedtopre-
vent intramolecular disulﬁde bond formation.
H. pylori UPPS H. pylori UPPS +
PPi
Data collection
Space group P212121
Resolution (˚ A)a 25 to 1.88 (1.95
to 1.88)
50 to 2.5 (2.59 to
2.5)
Unit cell dimensions
a, b, c (˚ A) 49.63, 58.91,
153.43
No. of reﬂections
Observed 201171 (18692) 137910 (12888)
Unique 35917 (3338) 15618 (1432)
Completeness (%) 95.4 (90.3) 96.0 (91.2)
Rmerge (%) 5.5 (43.3) 5.9 (15.9)
I/σ(I) 30.7 (4.1) 42.3 (5.2)
Reﬁnement
No. of reﬂectionsb 34629 (3038) 15084 (1330)
Rwork (%) 19.34 (22.91) 21.44 (30.24)
Rfree (%) 24.00 (30.02) 29.33 (37.43)
Geometry deviations
Bond lengths (˚ A) 0.0193 0.0061
Bond angles (◦) 1.817 1.157
No. of all non-H atoms 3463 3449
No. of water molecules 581 134
Mean B-values (˚ A2) 39.54 49.49
Ramachandran plot (%)
Most favored 92.1 92.3
Additionally allowed 7.9 7.7
aValues in the parentheses are for the highest resolution shells.
bAll positive reﬂections are used in the reﬁnements.
NMR System (CNS) program [18]. The orthorhombic crys-
tal contained one UPPS dimer in an asymmetric unit. The
models of PDB 1V7U (E. coli UPPS structure bound with
FPP, chain A) [13] were used as search model to yield a good
resolution for the H. pylori UPPS. The space group was de-
termined as P212121. With all solvent and cofactor molecules
removed, the model yielded an initial R-value of 0.50 using
a l lp o s i t i v er e ﬂ e c t i o n sa t1 . 8 8˚ A resolution upon rigid-body
reﬁnement.
The 2Fo-Fc diﬀerence Fourier map showed clear elec-
tron densities for most amino acid residues. The residues
of catalytic loop of 58–67 in chain A, 56–71 and 150–158
in chain B were disordered. Subsequent reﬁnement with in-
corporation of 581 water molecules according to 1.0 σ map
level yielded R and Rfree values of 0.193 and 0.240, respec-
tively, at 1.88 ˚ A resolution. By employing similar procedures,
the C234A H. pylori UPPS and the FsPP-complexed struc-
tures were reﬁned with the addition of cofactor and solventChih-Jung Kuo et al. 3
molecules. All manual modiﬁcations of the models were per-
formed on an SGI Fuel computer using the program O [19].
Computational reﬁnements, which included maximal like-
lihood and simulated-annealing protocols, were carried out
usingCNS.TheprogramsMolScript[20],andRaster3D[21]
were used in producing ﬁgures.
2.4. Computerscreeningtoidentifytheinhibitors
The X-ray structure of H. pylori UPPS reported here and the
complex structure of E. coli UPPS (PDB code 1V7U) were
chosenasthetemplatesinthevirtualscreening.Theprogram
GOLD V2.1 was used to screen Maybridge database, a com-
mercially available compound database obtained from May-
bridge Chemical Company (Tintagel, Cornwall, England).
The binding pocket for the docking study was deﬁned as a
15 ˚ A radius sphere centered on the active site Asp13 of H.
pylori UPPS or Asp26 of E. coli UPPS. The scoring func-
tion,GoldScore,implementedinGOLDwasusedtorankthe
docking positions of the compounds. 26 compounds with
the highest score ranked by GoldScore were selected for inhi-
bition assays.
2.5. IC50 determination
The IC50 values of the two hits were measured in a buﬀer of
100mM Hepes (pH 7.5), 50mM KCl, 0.5mM MgCl2,a n d
0.1% Triton X-100, containing 0.05μMo fE. coli or H. py-
loriUPPS.Theconcentrationsofinhibitorsusedwereranged
from 0 to 500μM. To obtain the IC50, the does-response
curveswereﬁttedwiththeequation,A(I) = A(0)×{1−[I/(I+
IC50)]},whereA(I)istheenzymeactivitywithinhibitorcon-
centration I, A(0) is enzyme activity without inhibitor, and I
is the inhibitor concentration.
3. RESULTS
3.1. 3DstructuresofH.pyloriUPPS
To develop structure-based inhibitors, the crystal structures
of H. pylori UPPS were solved in this study. One is the
structure of H. pylori UPPS containing C234A mutation to
prevent intra-molecular disulﬁde bond formed during the
long period of crystallization process (Figure 1(a)), and the
other is the structure of C234A complexed with FsPP, but
only the pyrophosphate portion is visible (Figure 1(b)). The
C234A mutant has unchanged kinetic property compared
with the wild type (k cat,F P PK m and IPP Km of C234A were
0.20±0.08s−1,0.15±0.04μMand9.6±0.2μM,almostequal
to0.22±0.05s−1,0.11±0.02μMand9.2±0.1μMforthewild
type, resp.). The overall structure of H. pylori UPPS was sim-
ilar to that of E. coli UPPS [22]. The protein is a dimer and
each subunit contains a catalytic domain and a pairing do-
main.Twosubunitsaretightlyassociatedthroughthecentral
β-sheet and a pair of long α-helices (α5a n dα6). However, H.
pylori UPPS has a 1.5-turn shorter α5 helix in the dimer in-
terface. This may weaken the dimer formation for H. pylori
UPPS.Thecatalyticdomainiscomposedofsixβ-strandsand
fourβ-helicesandthecentraltunnel-shapedactivesiteissur-
rounded by 2 α-helices (α2a n dα3) and 4 β-strands (βA-βB-
βD-βC) (Figure 1(a)).
At the bottom of the tunnel, a large amino acid F124 oc-
cupies a similar position to that of L137 at the bottom of
E. coli UPPS tunnel, which is a key residue to shield the ﬁ-
nal product and determine its chain length [22]. At the top
of this tunnel, several amino acids including D13, R17, R26,
H30, F57, S58, R180, and E184 are located in the substrate
binding site (Figure 1(b)). The position of the pyrophos-
phate (shown in black sticks in Figure 1(b)) of FsPP in the
complex is almost identical to that of the FPP pyrophosphate
in the E. coli UPPS active site [13].
Thepositionsoftheα3helixinthetwosubunitsofH.py-
lori UPPS are slightly diﬀerent (Figure 1(a)), resembling the
open and closed forms of E. coli UPPS [22]. H. pylori UPPS
A-chain strongly resembles the Triton-bound open form of
E. coli UPPS [23], with root mean square deviation (r.m.s.d)
of 0.78 ˚ A for 200 match pairs of α-carbon atoms. Compare to
the closed-form structure of E. coli UPPS with FsPP and IPP
bound [9], the H. pylori UPPS B-chain is with the r.m.s.d. of
1.08 ˚ A for 191 match pairs of α-carbon atoms. This suggests
a conformational change in the H. pylori UPPS reaction.
3.2. VirtualscreeningoftheH.pyloriUPPSinhibitors
Based on the structures, computer virtual screening was
carried out to search for selective inhibitors of E. coli and
H. pylori UPPS. The screening procedure is summarized in
Figure 2. The crystal structure of E. coli UPPS bound with
FPP (1V7U) was used as a template ﬁrst for the virtual
screening since the electron density of a small loop responsi-
ble for conformational change near the active site is not vis-
ible in H. pylori UPPS, which might confound the virtual
screening result. A compound database containing 58,635
compounds available from Maybridge Chemical Company
were screened using the program GOLD V2.1. Each com-
poundinthedatabasewasdockedintotheactivesiteofE.coli
UPPS, deﬁned as 15 ˚ A radius sphere around Asp26, an essen-
tialresidueresponsibletocoordinatewiththecatalyticMg2+.
The docked molecules were then ranked by the GoldScore
ﬁtness function, according to the sum of H-bond energy, van
der Waals energy, internal ligand van der Waals and inter-
nal torsional strain energy. The top 26 compounds ranked
by GoldScore were then purchased and experimentally eval-
uated for their ability to inhibit H. pylori and E. coli UPPS.
3.3. InhibitionagainstE.coliandH.pyloriUPPS
Of these 26 compounds, 2 compounds numbered BTB06061
and HTS04781, were found inhibitory to H. pylori UPPS al-
most equally with IC50 values of 350μM and 362μM, re-
spectively (Figure 3). The IC50 values of these two com-
pounds against the C234A and wild-type enzyme were al-
most equal. As revealed by the predicted models shown
in Figures 3(a) and 3(b), two inhibitors are likely bound
to H. pylori UPPS with a similar orientation to that of
the substrate FPP. The sulfur atom in the thiazole ring of
BTB06061 may form H-bonds with Asn15 and His30 while
the SO2 group is hydrogen bound with Met12. In addition,4 Journal of Biomedicine and Biotechnology
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Figure 1: Crystal structures of H. pylori UPPS. (a) Two subunits of the apoenzyme are superimposed. The most obvious disposition occurs in
α3helixwhichadoptsanopenformandaclosedforminsubunitAandB,respectively.Atthetopofthetunnel-shapedcrevicesurroundedby
2α-helices and 4β-strands is the substrate-binding site. Phe124 located at the bottom of the H. pylori UPPS tunnel adopts a similar position
to that of Leu137 in E. coli UPPS, essential for determining product chain length. (b) Superimposition of active site structures of H. pylori
UPPS with FsPP and E. coli UPPS with FsPP, Mg2+,a n dI P P[ 9]. The active site residues in H. pylori UPPS are shown in pink and those in E.
coli UPPS in white for carbon-carbon bonds in ball-and-stick model. The thiopyrophosphate (visible in crystal structure) is shown in black,
the nitrogen atoms and Mg2+ ion are shown in blue, and oxygen atoms are shown in red. Asp13 in H. pylori UPPS occupies a similar position
to that of Asp26 in E. coli UPPS to coordinate with an Mg2+ for binding with the pyrophosphate leaving group of FPP.
H. pylori UPPs Maybridge compounds
(58635)
GOLD V.2.1
Active site around Asp13 (68)
Fitness (21)
Fitness diﬀ.
mode (5)
H-bond energy (22)
VDW energy (9)
Rescore by Glide (11) BTB 06061
HTS 04781
Figure 2: The ﬂow chart for computer screening of H. pylori UPPS
inhibitors. The active zone for screening was focused on Asp13,
an important amino acid residue for coordinating with catalytic
Mg2+. In parentheses are the numbers of compounds. BTB06061
and HTS04781 are the ﬁnal hits.
the aromatic rings of BTB06061 form hydrophobic interac-
tions with the surrounding hydrophobic residues, including
Val34, Leu37, Ala56 and Tyr79. As shown in the predicted
model of HTS04781 with H. pylori UPPS, the sulfonamide
group forms H-bonds with Gly16 and Arg26 and the N atom
in the tetracyclic ring is hydrogen bound to the main chain
ofMet12.Extensivehydrophobicinteractionswerefoundbe-
tween the tetracyclic ring with the surrounding residues in-
cluding Met12, His30, Gly33 and Val34.
Surprisingly, BTB06061 showed 5-fold smaller IC50
(71μM) against E. coli UPPS and HTS04781 almost did not
inhibit E. coli UPPS, although two compounds inhibited H.
pylori equally. From the modeling (not shown), the smaller
entrance in E. coli UPPS compared to H. Pylori UPPS at the
top of the tunnel due to the partial blockage by the amino
acidssuchasTrp75fromtheﬂexibleloopmightrestrict,orat
least partially limit the access of bulky compound HTS04781
that contains four rigid aromatic rings to the active site,
thereby leading to the loss of inhibitory activity when com-
peting with the substrate for binding.
4. DISCUSSION
In this paper we describe the crystal structures of UPPS from
H. pyroli, a wide-spreading and life-threatening pathogen,
and the ﬁrst structure-derived inhibitors from computer
virtual screening. Although a high-throughput screening
has been performed for UPPS by a pharmaceutical com-
pany [24], none of the inhibitors have been reported. So
far, a series of IPP analogues with a dicarboxylate moiety
in place of the diphosphate were synthesized and the E-
pentenylbutanedioic acid showed inhibition of UPPS with
an IC50 of 135μM[ 25]. Based on the known structure of
UPPS (9), two carboxylate groups may coordinate with the
catalytic Mg2+ ion which was bound with the pyrophosphate
group of the substrates. Recently, we reported some bis-
phosphonates, which inhibited trans-type FPPs, which could
also inhibit cis-type UPPS with sub-μMI C 50 when con-
taining suitable hydrophobic side-chains [26]. The crystalChih-Jung Kuo et al. 5
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Figure 3: Computer virtual screening of the H. pylori UPPS inhibitors. Two compounds, BTB06061 shown in (a) and HTS04781 in (b),
were identiﬁed from the computer ﬁtting of the Maybridge compounds into the active site of E. coli and H. pylori UPPS. The data of
enzyme activities in the presence of diﬀerent concentrations of the inhibitors were used to determine the IC50 values of the inhibitors. The
compounds displayed IC50 of 350 and 363μM, respectively, in inhibiting H. pylori UPPS activity. However, the IC50 of BTB06061 became
71μM in inhibiting E. coli UPPS and HTS04781 was almost inactive against the enzyme. The modeled structures of the inhibitor bound in
t h ea c t i v es i t eo fH. pylori UPPS are shown at the bottom.
structures show that four molecules of inhibitors are bound
in the active site and one of them occupies the FPP site
with a phosphoate group chelating with the Mg2+.H e r e ,
we report the ﬁrst two novel inhibitors identiﬁed from a
randomized compound library through virtual screening.
These two inhibitors likely occupy the FPP site of H. py-
lori UPPS based on computer modeling. Two inhibitors dis-
played similar inhibition against H. pylori UPPS, but very
diﬀerent inhibition on E. coli UPPS. The one with bulky
skeleton did not inhibit E. coli UPPS, likely owing to the
partially blocked opening at the top of tunnel by the ﬂex-
ible loop in the E. coli UPPS active site. Our results shed
light on the possibility of developing antibiotics specially tar-
geting pathogenic H. pylori without killing the intestinal E.
coli.
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